Modeling the influence of cyclodextrins on oral absorption of low-solubility drugs: I. Model development

Biotechnology and Bioengineering

Volumn 105, Issue 2, 2010, Pages 409-420

  Gamsiz, Ece Dilber ^a   Miller, Lee ^b,c   Thombre, Avinash G ^b   Ahmed, Imran ^b   Carrier, Rebecca Lyn ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bioavailability; Cyclodextrins; Modeling; Poorly soluble drugs

Indexed keywords

BINDING CONSTANT; BIOAVAILABILITY; CDS; COMPLEXATION REACTION; CONTROLLED RELEASE; CYCLIC OLIGOSACCHARIDES; DOSAGE FORMS; DRUG ABSORPTION; DRUG DISSOLUTION; FORMULATION DESIGN; INCLUSION COMPLEX; INTESTINAL LUMEN; MASS TRANSPORT; MODEL DEVELOPMENT; MOLAR RATIO; NEUTRAL COMPOUNDS; NEUTRAL DRUGS; ORAL ABSORPTION; PARAMETER VALUES; PHYSICAL AND CHEMICAL PROPERTIES; PHYSICAL MIXTURES; PSEUDO-EQUILIBRIUM; SIMULATION RESULT;

ABSORPTION; BIOCHEMISTRY; COMPLEXATION; CYCLODEXTRINS; DATA STORAGE EQUIPMENT; DISSOLUTION; DRUG DELIVERY; DRUG INTERACTIONS; DRUG PRODUCTS; MIXTURES; MODELS; SOLUBILITY; TERNARY SYSTEMS;

DRUG DOSAGE;

CYCLODEXTRIN DERIVATIVE;

ARTICLE; COMPLEX FORMATION; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MIXTURE; DRUG RELEASE; DRUG SOLUBILITY; INTESTINE; MATHEMATICAL MODEL; SIMULATION;

ABSORPTION; ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CYCLODEXTRINS; DRUG CARRIERS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 74849087408     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22523     Document Type: Article

References (47)

1. Agoram B, Woltosz WS, Bolger MB. 2001. Predicting the impact of physiological and biochemical processes on drug bioavailability. Adv Drug Del Rev S1(50):S41-S67.
2. Arima H, Hirayama F, Okamoto CT, Uekama K. 2002. Recent aspects of cyclodextrin-based pharmaceutical formulations. Recent Res Dev Chem Pharm Sci 2:155-193.
3. Cameron KS, Fielding L. 2002. NMR diffusion coefficient study of steroidcyclodextrin inclusion complexes. Mag Resonance Chem 40:S106-S109.
4. Carrier RL, Miller LA, Ahmed I. 2007. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release 123(2):78-99.
5. Challa R, Ahuja A, Ali J, Khar RK. 2005. Cyclodextrins in drug delivery: An updated review. AAPS PharmSciTech 6(2):E329-E357.
6. Davis ME, Brewster ME. 2004. Cyclodextrin-based pharmaceutics: Past, present and future. Nat Rev Drug Discovery 3(12):1023-1035.
7. Dressman JB, Fleisher D. 1986. Mixing-tank model for predicting dissolution rate control or oral absorption. J Pharm Sci 75(2):109-116.
8. Dressman JB, Fleisher D, Amidon GL. 1984. Physicochemical model for dose-dependent drug absorption. J Pharm Sci 73(9):1274-1279.
9. Dressman JB, Amidon GL, Fleisher D. 1985. Absorption potential: Estimating the fraction absorbed for orally administered compounds. J Pharm Sci 74(5):588-589.
10. Emara LH, Badr RM, Elbary AA. 2002. Improving the dissolution and bioavailability of nifedipine using solid dispersions and solubilizers. Drug Dev Ind Pharm 28(7):795-807.
11. Erden N, Celebi N. 1988. A study of the inclusion complex of naproxen with b-cyclodextrin. Int J Pharm 48(1-3):83-89.
12. Hintz RJ, Johnson KC. 1989. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm 51(1):9-17.
13. Hirayama F, Horikawa T, Yamanaka M, Uekama K. 1995. Enhanced bioavailability and reduced metabolism of salbutamol by perbutanoyl-b- cyclodextrin after oral administration in dogs. J Pharm Sci 1(11):517-520.
14. Hogben CA, Tocco DJ, Brodie BB, Schanker LS. 1959. On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther 125(4):275-282.
15. Kikuchi M, Hirayama F, Uekama K. 1987. Improvement of oral and rectal bioavailabilities of carmofur by methylated b-cyclodextrin complexations. Int J Pharm 38(1-3):191-198.
16. Langer R, Peppas NA. 2003. Advances in biomaterials, drug delivery, and bionanotechnology. AIChE J 49(12):2990-3006.
17. Loftsson T, Brewster ME. 1996. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 85(10):1017-1025.
18. Loftsson T, Brewster ME, Masson M. 2004. Role of cyclodextrins in improving oral drug delivery. Am J Drug Del 2(4):261-275.
19. Miyake K, Arima H, Hirayama F, Yamamoto M, Horikawa T, Sumiyoshi H, Noda S, Uekama K. 2000. Improvement of solubility and oral bioavailability of rutin by complexation with 2-hydroxypropyl-beta-cyclodextrin. Pharm Dev Technol 5(3):399-407.
20. Mosher GL, Thompson DO. 2002. Complexation and cyclodextrins. In: Swarbrick J, editor. Encyclopedia of pharmaceutical technology. New York, NY: Marcel Dekker.
21. Nakanishi K, Nadai T, Masada M, Miyajima K. 1992. Effect of cyclodextrins on biological membrane. II. Mechanism of enhancement on the intestinal absorption of non-absorbable drug by cyclodextrins. Chem Pharm Bull 40(5):1252-1256.
22. Nambu N, Shimoda M, Takahashi Y, Ueda H, Nagai T. 1978. Pharmaceutical interaction in dosage forms and processing. Part IX. Bioavailability of powdered inclusion compounds of nonsteroidal antiinflammatory drugs with b-cyclodextrin in rabbits and dogs. Chem Pharm Bull 26(10):2952-2956.
23. Otero-Espinar FJ, Anguiano-Igea S, Garcia-Gonzalez N, Vila-Jato JL, Blanco-Mendez J. 1991. Oral bioavailability of naproxen-b-cyclodextrin inclusion compound. Int J Pharm 75(1):37-44.
24. Rajewski RA, Stella VJ. 1996. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci 85(11):1142-1169.
25. Reddy DN, Singh UV, Pandey S, Udupa N. 1992. Evaluation of piroxicam oral and transdermal preparations. Indian J Pharm Sci 54(4):152-154.
26. Savolainen J, Jarvinen K, Taipale H, Jarho P, Loftsson T, Jarvinen T. 1998. Co-administration of a water-soluble polymer increases the usefulness of cyclodextrins in solid oral dosage forms. Pharm Res 15(11):1696-1701.
27. Schanker LS, Shore PA, Brodie BB, Hogben CAM. 1957. Absorption of drugs from the stomach. I. The rat. J Pharmacol Exp Ther 120:528-539.
28. Schanker LS, Tocco DJ, Brodie BB, Hogben CA. 1958. Absorption of drugs from the rat small intestine. J Pharmacol Exp Ther 123(1):81-88.
29. Shore PA, Brodie BB, Hogben CA. 1957. The gastric secretion of drugs: A pH partition hypothesis. J Pharmacol Exp Ther 119(3):361-369.
30. Stella VJ, Rajewski RA. 1997. Cyclodextrins: Their future in drug formulation and delivery. Pharm Res 14(5):556-567.
31. Strickley RG. 2004. Solubilizing excipients in oral and injectable formulations. Pharm Res 21(2):201-230.
32. Szejtli J. 1988. Cyclodextrin technology. Dordrecht: Kluwer Academic Publishers.
33. Szejtli J. 1994. Medicinal applications of cyclodextrins. Med Res Rev 14(3): 353-386.
34. Thompson DO. 1997. Cyclodextrins-enabling excipients: Their present and future use in pharmaceuticals. Crit Rev Ther Drug Carr Syst 14(1): 1-104.
35. Uekama K. 2004. Design and evaluation of cyclodextrin-based drug formulation. Chem Pharm Bull 52(8):900-915.
36. Uekama K, Otagiri M. 1987. Cyclodextrins in drug carrier systems. Crit Rev Ther Drug Carr Syst 3(1):1-40.
37. Uekama K, Fujinaga T, Otagiri M, Seo H, Tsuruoka M. 1981. Enhanced bioavailability of digoxin by gamma-cyclodextrin complexation. J Pharmacobiodyn 4(9):735-737.
38. Uekama K, Otagiri M, Uemura Y, Fujinaga T, Arimori K, Matsuo N, Tasaki K, Sugii A. 1983. Improvement of oral bioavailability of prednisolone by b-cyclodextrin complexation in humans. J Pharmacobiodyn 6(2): 124-127.
39. Usuda M, Endo T, Nagase H, Tomono K, Ueda H. 2000. Interaction of antimalarial agent artemisinin with cyclodextrins. Drug Dev Ind Pharm 26(6):613-619.
40. Vila-Jato JL, Blanco J, Vilar A. 1986. Spironolactone/b-cyclodextrin complex: Oral bioavailability in humans. Acta Pharm Technol 32(2):82-85.
41. Vila-Jato JL, Blanco J, Torres JJ. 1988. Biopharmaceutical aspects of the tolbutamide-b-cyclodextrin inclusion compound. Farmaco Edizione Pratica 43(2):37-45.
42. Waterman KC, Sutton SC. 2003. A computational model for particle size influence on drug absorption during controlled-release colonic delivery. J Control Release 86(2-3):293-304.
43. Wong JW, Yuen KH. 2001. Improved oral bioavailability of artemisinin through inclusion complexation with b- and g-cyclodextrins. Int J Pharm 227(1-2):177-185.
44. Yu LX. 1999. An integrated model for determining causes of poor oral drug absorption. Pharm Res 16(12):1883-1887.
45. Yu LX, Lipka E, Crison JR, Amidon GL. 1996. Transport approaches to the biopharmaceutical design of oral drug delivery systems: Prediction of intestinal absorption. Adv Drug Del Rev 19(3):359-376.
46. Yunomae K, Arima H, Hirayama F, Uekama K. 2001. Contribution of Pglycoprotein to enhancing effects of dimethyl b-cyclodextrin on oral bioavailability of tacrolimus in rats. Proceedings - 28th International Symposium on Controlled Release of Bioactive Materials and 4th Consumer & Diversified Products Conference, San Diego, CA, United States, June 23-27, 2001;1712-1713.
47. Yunomae K, Arima H, Hirayama F, Uekama K. 2003. Involvement of cholesterol in the inhibitory effect of dimethyl-beta-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. FEBS Lett 536 (1-3):225-231.